Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A2 | P31213 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 13/20 | 0.36 |
| ▸ | SHBG | P04278 | 1/20 | 0.33 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2319038 | 0.87 | SRD5A2 (0.39) | SRD5A2CYP3A4CYP2C9CYP2C19TDP1 | |
| SCHEMBL2339044 | 0.87 | SRD5A2 (0.39) | SRD5A2CYP3A4CYP2C9CYP2C19TDP1 | |
| SCHEMBL2334303 | 0.79 | SRD5A2 (0.38) | SRD5A2CYP3A4CYP2C9CYP2C19TDP1 | |
| SCHEMBL2318525 | 0.79 | SRD5A2 (0.38) | SRD5A2CYP3A4CYP2C9CYP2C19TDP1 | |
| SCHEMBL3643478 | 0.79 | CYP19A1 (0.55) | CYP3A4CYP2C19ALDH1A1CYP19A1SHBG | |
| SCHEMBL3359727 | 0.79 | CYP3A4 (0.45) | SRD5A2CYP3A4CYP2C9CYP2C19TDP1 | |
| SCHEMBL3238794 | 0.79 | CYP3A4 (0.45) | SRD5A2CYP3A4CYP2C9CYP2C19TDP1 | |
| SCHEMBL10532677 | 0.77 | SRD5A2 (0.37) | SRD5A2 | |
| SCHEMBL12973080 | 0.76 | SRD5A2 (0.39) | SRD5A2CYP3A4CYP2C9CYP2C19TDP1 | |
| SCHEMBL12904891 | 0.76 | SRD5A2 (0.43) | SRD5A2ALDH1A1CYP19A1SHBG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2170925-B1 | 17ß -CYANO-19-NOR-ANDROST-4-ENE DERIVATIVE, USE THEREOF AND MEDICAMENTS CONTAINING SAID DERIVATIVE | BAYER IP GMBH (DE) | 2012-10-24 | — | — | EP | disclosed |
| US-8207150-B2 | 17β-cyano-19-nor-androst-4-ene derivative, its use and medicaments comprising the derivative | Bayer Pharma AG (DE) | 2012-06-26 | — | — | US | disclosed |
| EP-2170925-A2 | 17ß -CYANO-19-NOR-ANDROST-4-ENE DERIVATIVE, USE THEREOF AND MEDICAMENTS CONTAINING SAID DERIVATIVE | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-04-07 | — | — | EP | disclosed |
| US-20090048217-A1 | 17Beta-CYANO-19-NOR-ANDROST-4-ENE DERIVATIVE, ITS USE AND MEDICAMENTS COMPRISING THE DERIVATIVE | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2009-02-19 | — | — | US | disclosed |
| WO-2008151746-A2 | 17β-CYANO-19-NOR-ANDROST-4-ENE DERIVATIVE, USE THEREOF AND MEDICAMENTS CONTAINING SAID DERIVATIVE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048217-A1 | 17Beta-CYANO-19-NOR-ANDROST-4-ENE DERIVATIVE, ITS USE AND MEDICAMENTS COMPRISING THE DERIVATIVE | HSD17B11, HSD17B7, NR5A1 | SRD5A2 12/4885CYP3A4 142/4885CYP2C9 193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.